MATERNAL DDAVP FOR TREATMENT OF OLIGOHYDRAMNIOS

母体 DDAVP 用于治疗水少症

• 批准号: 6117100
• 负责人: Michael Glenn Ross
• 金额: $ 3.89万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117100
• 关键词: amniotic fluid; arginine vasopressin; body water; body water dehydration; clinical research; hormone therapy; human pregnant subject; human therapy evaluation; outcomes research; pregnancy disorder; pregnancy disorder chemotherapy; urine

Potential therapeutic utility of maternal dDAVP for patients with oligohydramnios (insufficient amniotic fluid). Despite the significant consequences of oligohydramnios, there are no established means to increase amniotic fluid volume prior to labor. Recent studies indicate the potential of a novel treatment for oligohydramnios, utilizing maternal administration of a drug (dDAVP) to hydrate mother&secondly baby with amniotic fluid. The baby hydrates in relation to mother&increases its urine production and thus amniotic fluid.

母体dDAVP对以下患者的潜在治疗效用 羊水过少（羊水不足）。增速出现明显 羊水过少的后果，没有既定的手段， 在分娩前增加羊水量。最近的研究表明 一种新的治疗羊水过少的方法， 母亲给药药物（dDAVP）以水合母亲和第二次 羊水中的婴儿婴儿的水合作用与 母亲&增加其尿液产量，从而羊水。